PortfoliosLab logoPortfoliosLab logo
IPO Date
Jan 3, 2023

Highlights

Total Revenue (TTM)
$7.83M
Gross Profit (TTM)
-$639.50K
EBITDA (TTM)
-$5.21M
Year Range
$3.08 - $120.00
Target Price
$45.00
ROA (TTM)
-8.01%
ROE (TTM)
-89.85%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

MLEC Performance Chart

Moolec Science SA Ordinary Shares (MLEC) is up 78.8% since the beginning of the year. At $7 per share, MLEC is trading 94.3% below its 52-week high of $120.


Loading charts...

S&P 500 Index

Returns By Period

Moolec Science SA Ordinary Shares (MLEC) has returned 78.84% so far this year and -94.31% over the past 12 months.


Moolec Science SA Ordinary Shares

1D
-0.29%
1M
-34.14%
YTD
78.84%
6M
-5.73%
1Y
-94.31%
3Y*
-75.30%
5Y*
10Y*

Benchmark (S&P 500 Index)

1D
0.13%
1M
5.25%
YTD
11.16%
6M
11.43%
1Y
28.20%
3Y*
21.12%
5Y*
12.66%
10Y*
13.75%
*Multi-year figures are annualized to reflect compound growth (CAGR)

MLEC Monthly Returns History

Based on dividend-adjusted daily data since Jan 3, 2023, MLEC's average daily return is -0.12%, while the average monthly return is -6.88%.

Historically, 31% of months were positive and 69% were negative. The best month was Feb 2026 with a return of +104.6%, while the worst month was Aug 2025 at -59.0%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 7 months.

On a daily basis, MLEC closed higher 39% of trading days. The best single day was Jan 6, 2023 with a return of +251.3%, while the worst single day was Jan 16, 2026 at -34.4%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202670.20%104.62%-55.49%90.03%-33.07%-9.30%78.84%
2025-5.44%-2.19%-24.31%32.11%8.14%-21.25%-49.21%-59.04%-25.19%-34.33%-37.89%-36.35%-96.82%
2024-19.51%-9.09%-23.33%2.90%-17.60%-5.99%-12.73%-9.36%1.02%-3.37%2.43%-8.05%-67.48%
2023-41.76%13.21%-32.00%-32.11%8.88%22.01%-13.86%3.79%-14.89%-15.00%5.46%-1.99%-72.97%

Benchmark Metrics

Moolec Science SA Ordinary Shares has an annualized alpha of -38.57%, beta of 0.84, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since January 04, 2023.

  • This stock participated in 198.51% of S&P 500 Index downside but only -159.59% of its upside - more exposed to losses than it benefited from rallies.
  • R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-38.57%
Beta
0.84
0.00
Upside Capture
-159.59%
Downside Capture
198.51%

Return for Risk

Risk / Return Rank

MLEC ranks 12 for risk / return — in the bottom 12% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.


MLEC Risk / Return Rank: 1212
Overall Rank
MLEC Sharpe Ratio Rank: 2121
Sharpe Ratio Rank
MLEC Sortino Ratio Rank: 99
Sortino Ratio Rank
MLEC Omega Ratio Rank: 1111
Omega Ratio Rank
MLEC Calmar Ratio Rank: 33
Calmar Ratio Rank
MLEC Martin Ratio Rank: 1717
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Moolec Science SA Ordinary Shares (MLEC) and compare them to S&P 500 Index.


MLECBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

-0.46

2.39

-2.84

Sortino ratio

Return per unit of downside risk

-1.15

3.25

-4.40

Omega ratio

Gain probability vs. loss probability

0.87

1.43

-0.56

Calmar ratio

Return relative to maximum drawdown

-0.97

3.11

-4.08

Martin ratio

Return relative to average drawdown

-1.12

14.38

-15.50

Dividends

Dividend History


Moolec Science SA Ordinary Shares doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Moolec Science SA Ordinary Shares. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Moolec Science SA Ordinary Shares was 99.88%, occurring on Dec 24, 2025. The portfolio has not yet recovered.

The current Moolec Science SA Ordinary Shares drawdown is 99.76%.


Related event

Drawdown

Fall

Recovery

Underwater

2025 bear market2025
-99.88%Dec 2025
2y 11mo
3y 4moJan 2023 - now
2023 bear market2023
-39.78%Jan 2023
1d1d
2dJan 2023 - Jan 2023

Drawdown Indicators


MLECBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-99.88%

-56.78%

-43.10%

Max Drawdown (1Y)

Largest decline over 1 year

-97.34%

-9.10%

-88.24%

Max Drawdown (3Y)

Largest decline over 3 years

-99.41%

-18.90%

-80.51%

Max Drawdown (5Y)

Largest decline over 5 years

-25.43%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

-99.76%

0.00%

-99.76%

Average Drawdown

Average peak-to-trough decline

-91.71%

-10.72%

-80.99%

Ulcer Index

Depth and duration of drawdowns from previous peaks

84.38%

1.97%

+82.41%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Moolec Science SA Ordinary Shares over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Moolec Science SA Ordinary Shares is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with MLEC

Add Moolec Science SA Ordinary Shares to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with MLEC